This week, ASFaVIP partners met in Berlin for a dedicated workshop focused on the development of the project’s model licensing dossier for African swine fever (ASF) vaccines.
While generating scientific evidence is a crucial step, translating these data into a format that meets regulatory expectations is equally important. Throughout the meeting, experts from across the consortium worked together to:
🔹 Review the structure of the licensing dossier in line with European regulatory requirements.
🔹 Consolidate evidence generated throughout the project on vaccine quality, safety and efficacy.
🔹 Discuss how project results can best support future regulatory evaluation of ASF vaccine candidates.
🔹 Identify remaining data gaps and define the next steps towards completion of the dossier.
By integrating scientific findings with regulatory considerations, ASFaVIP aims to facilitate future vaccine development and contribute to preparedness against African swine fever.
